glp-1 agonist eli lilly stock soars on encouraging results for daily weight-loss pill Orforglipron: Eli Lilly's New Oral

The clinically most relevant and important action of DPP-4 inhibitors is the endogenous elevation of the incretin hormone concentration of GLP-1 that consecutively leads to a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion (10)

Ethics declarations Conflict of Interest Neil Gupta, Zaid Zayyad, Rohan Bhattaram, David Tiu, Jennifer Dau, Stephanie Dwyer Kalzuna, Vidur Gurbuxani, and Adhir R

Drug interactions and metabolism Weight loss associated with GLP-1R use may alter drug metabolism of weight-based medications (e.g., levothyroxine, warfarin )

Stronger cardiovascular data: The SELECT trial provides robust evidence for cardiovascular protection

51 Addressing these adverse effects is crucial for improving patient compliance and therapeutic outcomes

Managing these conditions effectively at an early stage with pharmaceutical interventions could lead to a decrease in the need for more aggressive treatments and hospitalizations in the long run, thereby saving healthcare costs